Medtronic Sees Unusually High Options Volume (NYSE:MDT)

Medtronic PLC (NYSE:MDT) was the recipient of some unusual options trading on Wednesday. Stock investors bought 143,524 call options on the stock. This represents an increase of approximately 1,013% compared to the average daily volume of 12,892 call options.

Medtronic Stock Performance

Medtronic stock traded up $0.01 during midday trading on Wednesday, hitting $97.48. 1,976,350 shares of the company were exchanged, compared to its average volume of 7,439,948. Medtronic has a fifty-two week low of $79.29 and a fifty-two week high of $106.33. The firm has a market capitalization of $124.97 billion, a PE ratio of 26.27, a price-to-earnings-growth ratio of 2.57 and a beta of 0.71. The business has a fifty day simple moving average of $97.44 and a two-hundred day simple moving average of $93.61. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter last year, the company earned $1.26 EPS. The business’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts forecast that Medtronic will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Friday, December 26th. Medtronic’s payout ratio is currently 76.55%.

Analysts Set New Price Targets

Several brokerages recently weighed in on MDT. Jefferies Financial Group restated a “hold” rating and set a $110.00 target price on shares of Medtronic in a research note on Wednesday, November 19th. Sanford C. Bernstein set a $111.00 target price on shares of Medtronic in a research note on Wednesday, November 19th. Stifel Nicolaus upped their price target on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Robert W. Baird set a $103.00 price objective on shares of Medtronic in a research note on Tuesday, December 16th. Finally, Wells Fargo & Company upped their target price on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.94.

Institutional Trading of Medtronic

Several institutional investors have recently bought and sold shares of the business. 1248 Management LLC acquired a new stake in shares of Medtronic in the first quarter valued at approximately $26,000. Delos Wealth Advisors LLC purchased a new position in shares of Medtronic during the 2nd quarter worth $27,000. Corundum Trust Company INC acquired a new position in shares of Medtronic during the 3rd quarter valued at about $27,000. Twin Tree Management LP acquired a new position in shares of Medtronic during the 1st quarter valued at about $29,000. Finally, Valley Wealth Managers Inc. acquired a new stake in Medtronic during the third quarter worth about $29,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).